

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT07299695

Status	RECRUITING
Phase	Phase 3
Sponsor	Argyrios Tzouvelekis
Enrollment	196 participants

Key Eligibility Criteria

Inclusion (11)

- Patients ≥ 18 years of age
- Patients with IPF diagnosis that fulfils ATS/ERS Consensus Criteria.
- Patients hospitalised with a definite or suspected AE-IPF diagnosis, as defined by the international working group criteria and as ascertained by the responsible Primary Investigator.
- The criteria of IPF-AE are as follows:
- Previous or concurrent diagnosis of IPF
- ... and 6 more (see full listing online)

Exclusion (11)

- Patients with acute worsening due to uncontrolled heart failure or pulmonary embolism.
- Patients with known hypersensitivity to corticosteroids, IVIG or any component of the study treatment.
- Patients with known IgA deficiency (IgA level <7 mg/dL)- to preclude IVIG reactions.
- Patients without a definite diagnosis of IPF or AE-IPF based on clinical, radiological, laboratory evaluation, and multidisciplinary discussion.
- Patients with active malignancy or currently receiving cancer treatment, except for basal cell or squamous cell skin cancer or low-risk prostate cancer (T1 or T2a stage with PSA <10 ng/dL). These criteria are aligned with current guidelines.
- ... and 6 more (see full listing online)

Locations (1 total)

Department of Respiratory Medicine, University Hospital of Patras, Pátrai, Greece